Market Overview

Bank of America Initiates Coverage on Jazz Pharmaceuticals Positive Outlook

Related JAZZ
Jazz Pharma Downgraded By Vetr
Why Is Jazz Pharmaceuticals (JAZZ) Down 3.3% Since the Last Earnings Report?

In a report published Monday, Bank of America initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and $74 price objective.

Bank of America reported that, “We initiated coverage of Jazz with a Buy rating and $74 PO, which is based on a sum-of-the-parts DCF analysis and does not require multiple expansion. We like Jazz's focus on areas with strong growth potential and franchise durability, and we expect strong sales and EPS growth over the next several years driven by Xyrem and Erwinaze.”

Jazz Pharmaceuticals closed at $56.03 on Monday.

Latest Ratings for JAZZ

May 2017RBC CapitalInitiates Coverage OnTop Pick
Apr 2017MizuhoDowngradesBuyNeutral
Feb 2017Evercore ISI GroupInitiates Coverage OnBuy

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Analyst Ratings


Related Articles (JAZZ)

View Comments and Join the Discussion!